<DOC>
	<DOCNO>NCT03062397</DOCNO>
	<brief_summary>Clinical Trial Evaluate Efficacy Safety JPI-289 Patients With Acute Ischemic Stroke</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety JPI-289 Patients With Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Subjects acute ischemic stroke , age â‰¥ 19 Confirmed acute anterior circulation cerebral artery occlusion intracranial internal carotid artery ( IICA ) middle cerebral artery ( MCA ) M1 segment CT MR angiography . National Institutes Health Stroke Scale ( NIHSS ) 6~30 endovascular recanalization therapy ( ERT ) Subject reperfused 2b 3 stage thrombolysis cerebral infarction ( TICI ) ( However , angiography conduct thrombectomy IV tPA treatment effect tPA result TICI 2b3 reperfusion , subject participate ) Subject administer IP within 6.5 hrs symptom development Subject administer IP within 30 min vascular reperfusion Subject evaluate MRI within 90 min vascular reperfusion Subject contraindicate endovascular recanalization Subject hypersensitivity contrast agent component investigational product Prohibited unable perform MRI test Medical history relate bleed History hemorrhagic stroke within 6 month study participation Subjects chronic liver disorder Kidney disorder ( Serum creatinine &gt; 3 mg/dL ) Life expectancy le 3 month due concomitant disease stroke Pregnant lactate woman Those take tirofiban ( anticoagulant agent ) endovascular recanalization therapy Those take investigational drug and/or medical instrument 12 week prior screen Subject unable follow Subject deem unable participate study opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>